RNA Interference News and Research

RSS

Study reveals key protein's role in balancing immune response to viral infections

Researchers have revealed the regulatory mechanism of a specific protein that plays a key role in balancing the immune response triggered by viral infections in mammal cells.

18 Apr 2024

New RNA therapy zilebesiran shows promise in lowering blood pressure

Zilebesiran, an RNA interference therapeutic, significantly reduces blood pressure in hypertension patients with a favorable safety profile, offering a potential biannual treatment option.

19 Feb 2024

Discovery of toxic and protective short RNAs associated with Alzheimer's disease and superior memory capacity

Researchers explored how Death Induced by Survival gene Elimination through the analysis of RNA-induced silencing complex-bound short RNAs in Alzheimer's disease models influences neuronal survival and correlates with neurotoxicity in AD.

22 Jan 2024

Short strands of toxic RNAs contribute to brain cell death and DNA damage in Alzheimer's

Alzheimer's disease, which is expected to have affected about 6.7 million patients in the U.S. in 2023, results in a substantial loss of brain cells.

18 Jan 2024

New drug zilebesiran effectively lowers blood pressure for six months, study finds

A single injection of the experimental medication zilebesiran was safe and effective in reducing systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months, as detailed in the Phase 2 of the KARDIA study, reported as late-breaking science today at the American Heart Association's Scientific Sessions 2023.

13 Nov 2023

Arrayed CRISPR Screening for Revolutionizing Target Discovery

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Ulrike Kuenzel, Associate Director in the Functional Genomics department at AstraZeneca about the application of arrayed CRISPR screening for target identification and more.

From Society for Laboratory Automation and Screening (SLAS) 27 Sep 2023

Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

From AMGEN 1 Sep 2023

Study sheds light on how SARS-CoV-2 virus switches between replication and packaging

Immediately after the infection of a cell in the throat or lungs, the SARS-CoV-2 virus works very hard to replicate, using the human cell's metabolic pathways to produce its proteins and make sure that its genetic material (the RNA genome) is copied.

21 Aug 2023

Newly discovered protein kinase shows promise for establishing future obesity and diabetes treatments

Researchers used genetically modified animal models to investigate the role of the newly discovered Traf2- and NCK-interacting protein kinase (TNIK) in obesity and metabolic dysfunction.

15 Aug 2023

Study discovers new mechanism for deadly tumor switch in prostate cancer

A study from the University of Michigan Rogel Cancer Center uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.

14 Aug 2023

Scientists unravel step-by-step activation process of protein with deep evolutionary history

Scientists have unraveled the step-by-step activation process of a protein with a deep evolutionary history in all domains of life, opening the door to harnessing its functions for use as a biotechnology tool.

26 Jul 2023

New findings expand the genotypic spectrum of NPRL3-associated focal epilepsy

Science China Life Sciences magazine recently reported on the research results of Tang Beisha's team from Xiangya Hospital of Central South University, Liu Jing Yu's team from the Institute of Neurology of the Chinese Academy of Sciences, and Zhang Luoying's team from Huazhong University of Science and Technology, including Du Shiyue, Zeng Sheng, and Song Li. Epilepsy has a complex etiology with 80% owing a genetic basis.

15 Jun 2023

New technology can deliver gene therapy directly to the lung

Scientists at UMass Chan Medical School have developed a technology to deliver gene therapy directly to lung tissue through intranasal administration, a development that could potentially create a new class of treatments for lung disease.

2 May 2023

Study shows SARS-CoV-2 causes DNA damage and elicits an altered DNA damage response

Researchers assessed the association between SARS-CoV-2 infection and DNA damage and cellular senescence.

14 Mar 2023

Study finds a new mammalian antiviral response pathway restricting poxviruses replication

In a recent study posted to the bioRxiv* preprint server, researchers identified a novel antiviral pathway different from the interferon (IFN) pathway that inhibited poxvirus(es) replication.

15 Feb 2023

Study identifies new tau regulators as viable therapeutic targets for Alzheimer's and other tauopathies

Neurodegenerative diseases affect millions of people worldwide and as our life expectancy increases, more individuals are expected to be affected in the coming decades.

16 Jan 2023

Research reveals a novel viral strategy in modulating stress granule formation to promote virus infection

Researchers illustrated a novel strategy likely employed by viruses to promote infection.

6 Dec 2022

SLU and industry partners report the first effective drug to treat rare, genetic liver disease

Researchers at Saint Louis University's School of Medicine, in collaboration with Arrowhead Pharmaceuticals and Takeda Pharmaceuticals, report the first effective drug to treat a rare, genetic liver disease that formerly could only be treated with a liver transplant.

26 Jul 2022

Lumasiran shows efficacy and acceptable safety in patients with PH1 and advanced kidney disease

In patients with PH1 and advanced kidney disease, including patients on hemodialysis, use of Lumasiran shows substantial reductions in plasma oxalate levels with acceptable safety.

14 Jul 2022

Researchers discover the first effective drug to treat rare, genetic liver disease

8 Jul 2022